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CORTACTIN is an actin-binding protein critically involved in cellular migration and invasion.
Here, we investigated the role of CORTACTIN in the pathophysiology of orohypopharynx
carcinoma – one of the major subtypes of head and neck cancer. To this end, we analyzed
CORTACTIN expression in tumor tissues from 89 orohypopharynx carcinoma patients in
relation to clinical parameters. We found that high tumoral CORTACTIN expression asso-
ciated with poor survival, higher T-stage, and higher lymph node metastasis (N-stage) in
these patients. Next, we combined the prognostic values of tumoral and stromal cell bio-
logical parameters in our patient cohort.We determined the potential interaction of tumoral
CORTACTIN with tumor-infiltrating neutrophils, which have been previously linked to poor
clinical outcome in orohypopharynx carcinoma patients with advanced disease. Interest-
ingly, we found that patients with both high tumoral CORTACTIN expression and high
neutrophilic infiltration had significantly worse clinical outcome than all other patients in our
cohort. These findings suggest that tumoral CORTACTIN and tumor-infiltrating neutrophils
might be functionally linked during progression of orohypopharynx carcinoma. In vitro, we
showed that neutrophils released soluble factors which phosphorylated CORTACTIN in
the tumor cells and promoted their migration. Furthermore, we demonstrated that strong
CORTACTIN phosphorylation significantly correlated with strong neutrophilic infiltration
in tumor tissues from orohypopharynx carcinoma patients. Taken together, our findings
unravel a novel mechanism of tumor-stroma interaction, which might be relevant for a
more accurate prognosis and improved therapeutic strategies in this tumor entity.
Keywords: cancer-related inflammation, tumor microenvironment, head and neck cancer, clinical outcome, tumor
migration
INTRODUCTION
Head and neck cancer (HNC) is the eighth most common type
of cancer worldwide. Despite multiple and aggressive therapeutic
interventions, there has been no fundamental improvement in the
5-year survival rates of the patients over the past decades (Jemal
et al., 2007; Choong and Vokes, 2008). Therefore, there is an urgent
need to: (i) identify clinicopathological parameters (biomarkers)
for accurate diagnosis, prognosis, and therapeutic prediction in
these patients and to (ii) understand the biology and molecular
mechanisms behind the respective biomarkers.
A number of studies investigated the role of cortical actin-
binding protein (CORTACTIN) as prognostic marker in different
types of cancer. CORTACTIN is a cytoplasmic protein which
promotes the rearrangement of the actin cytoskeleton. Conse-
quently, CORTACTIN is critically involved in regulation of cellular
motility/migration, invasion, or endocytosis/vesicular trafficking
(reviewed in Ammer and Weed, 2008). To exert its functions, COR-
TACTIN needs to be activated by tyrosine or serine/threonine
phosphorylation. In particular, tyrosine phosphorylation of COR-
TACTIN at residues Tyr 421, Tyr 466, and Tyr 482 has often been
shown to occur in response to various stimuli (Ammer and Weed,
2008). Consistent with its role in cellular migration and invasion,
high CORTACTIN expression and/or activation has been found to
associate with increased metastasis and poor clinical outcome in
several types of cancer, such as renal carcinoma (Wang et al., 2009),
gastric cancer (Li et al., 2008), colorectal adenocarcinoma (Cai
et al., 2010), or melanoma (Xu et al., 2010). In HNC, amplifica-
tion of CORTACTIN gene has been linked to poor clinical outcome
mainly in patients with laryngeal carcinoma (Gibcus et al., 2008;
Rodrigo et al., 2009).
Solid tumors display an inflammatory microenvironment,
characterized by large numbers of tumor-associated immune cells,
which represent a biologically important component of the tumor-
stroma (Coussens and Werb, 2002; Lin and Karin, 2007). Within
the tumor microenvironment, cancer cells can “reprogram” the
stromal immune cells of the host to acquire tumor-promoting
activities. Although less characterized than tumor-associated
macrophages (TAMs) or tumor-infiltrating lymphocytes (TILs),
tumor-infiltrating neutrophils are emerging as important play-
ers in the pathophysiology of cancer. Within the tumor tissue,
neutrophils can potentially modulate multiple cellular processes
which may ultimately lead to tumor progression. In particular,
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neutrophils were shown to promote angiogenesis (Nozawa et al.,
2006; Jablonska et al., 2010; Bekes et al., 2011; Kuang et al., 2011).
However, neutrophils can directly modulate the biology and func-
tions of tumor cells by promoting their migration, invasion, or
proliferation (reviewed in Gregory and Houghton, 2011; Dumitru
et al., 2012b). Thus, it is not surprising that very recent studies
reported an association of high numbers of tumor-infiltrating
neutrophils with advanced disease and poor clinical outcome
in patients with different types of cancer, such as renal cancer
(Donskov and von der Maase, 2006; Jensen et al., 2009), hepato-
cellular cancer (Kuang et al., 2011), non-small-cell lung carcinoma
(NSCLC; Ilie et al., 2012), or melanoma (Jensen et al., 2012).
Recently, we demonstrated that high neutrophilic infiltration of
the tumor tissue associated with high tumor (T) stage and poor
survival in head and neck (orohypopharynx) cancer patients with
advanced disease (Trellakis et al., 2011). Furthermore, our in vitro
studies indicated a direct interaction between neutrophils and
HNC cells by showing that neutrophils were “primed” by the
tumor cells to release pro-inflammatory factors which promoted
tumoral migration in a feed-back manner (Dumitru et al., 2011,
2012a).
In the present study we characterized the tumor-neutrophil
interactions in orohypopharyngeal cancer with particular focus
on the role of tumoral CORTACTIN in this process. We demon-
strate that high tumoral CORTACTIN levels together with high
neutrophilic infiltration predict poor clinical outcome in univari-
ate and multivariate analysis. These findings suggest that tumoral
CORTACTIN and tumor-infiltrating neutrophils “cooperate” in
the progression of orohypopharynx carcinoma. Further in vitro
and in situ studies confirm the clinical findings and demonstrate
that neutrophils activate (phosphorylate) CORTACTIN in the
tumor cells to promote their migration.
MATERIALS AND METHODS
STUDY SUBJECTS
Neutrophils were isolated from the peripheral blood of healthy
volunteers. For immunohistochemical studies on frozen sections,
malignant tissues were collected from 37 patients with orohy-
popharyngeal cancer, treated at the Department of Otorhinolaryn-
gology (University of Duisburg-Essen) between 2010 and 2012.
Healthy epithelial tissues (n= 12) were collected from contralat-
eral buccal mucosa of the same patients. For immunohistochem-
ical studies on tissue microarrays (TMAs) and correlation with
clinical parameters, tissue samples were collected from 89 patients
with head and neck squamous cell carcinoma of the oropharynx
and hypopharynx. The patients were treated at the Department
of Otorhinolaryngology (University of Duisburg-Essen) between
1995 and 2000 and clinical follow-up was retrieved. The charac-
teristics of these patients are shown in Table 1. All studies were
approved by the ethics committee of the University Hospital Essen
(nr. 09-4074, nr. 07-3500, and nr. 12-5192-BO).
CELL LINES, CONDITIONED SUPERNATANTS, AND siRNA
TRANSFECTIONS
The human hypopharyngeal carcinoma cell line FaDu was
obtained from the American Type Culture Collection (ATCC,
Table 1 | Characteristics of the patients used forTMA analysis and
association with clinical parameters (survival,T-stage, and N-stage).
Number % of total
All patients 89 100
GENDER
Male 71 79.8
Female 18 20.2
TUMOR LOCALIZATION
Oropharynx 65 73.0
Hypopharynx 24 27.0
T-STAGE
T1 13 14.6
T2 19 21.3
T3 12 13.5
T4 45 50.6
N-STAGE
NO 14 15.7
N1 13 14.6
N2a 6 6.7
N2b 20 22.5
N2c 32 36.0
N3 4 4.5
DISTANT METASTASIS
MO 86 96.6
M1 3 3.4
HISTOLOGIC GRADE
Grade 1 6 6.7
Grade 2 55 61.8
Grade 3 28 31.5
Manassas, VA, USA). The cells were cultured and main-
tained in RPMI-1640 (Invitrogen, Karlsruhe, Germany) sup-
plemented with 10% fetal calf serum (Biochrom, Berlin,
Germany), 100 units/mL penicillin, and 100 (g/mL strepto-
mycin (PAA-Laboratories GmbH, Coelbe, Germany). To obtain
tumor-conditioned supernatants (FaDu SN), we incubated
2× 106 cells/mL for 24 h at 37˚C in RPMI-1640 supplemented
as above. The resulting supernatant was centrifuged to remove
cellular debris and stored at−20˚C.
To knock-down CORTACTIN, we transfected FaDu cells with
25 nM validated CORTACTIN siRNA or 25 nM AllStars Nega-
tive Control (mock) siRNA (both from Qiagen, Hilden, Germany)
using the NEON™ transfection system (Invitrogen, Karlsruhe,
Germany).
MIGRATION ASSAY
Migration of FaDu cells was assessed with the ORIS™ cell migra-
tion system (Platypus Technologies, Madison, WI, USA) accord-
ing to the manufacturer’s instructions. The cells were allowed to
migrate for 48 h and were then fixed/stained with a solution con-
taining 2% formaldehyde, 30% ethanol, 60 mM NaCl, and 0.7%
crystal violet. Micrographs were taken at 25× magnification and
quantification of “gap”-closure was performed with the ImageJ
software.
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ISOLATION AND CULTURE OF NEUTROPHILS
Neutrophils (purity >98%) were isolated from the blood of
healthy donors as previously described (Dumitru et al., 2011) and
were cultured in RPMI-1640 supplemented as above.
AMIDA SCREENING
Tumors elicit an immune response, leading to the generation
of antibodies specific for tumoral antigens. AMIDA technology
(autoantibody-mediated identification of antigens) identifies pro-
teins exclusively recognized by antibodies from cancer patients
but not from healthy controls. Here, we used AMIDA to screen
for tumor-associated antigens in four HNC patients versus four
healthy donors. The screening was performed exactly as described
previously (Rauch et al., 2004).
ANTIBODIES AND INHIBITORS
Polyclonal rabbit anti-human CORTACTIN and rabbit IgG anti-
bodies were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Rabbit anti-human phospho-CORTACTIN (Tyr421)
antibodies were from Cell Signaling Technology (Danvers, MA,
USA) or from Millipore (Temecula, CA, USA). Rabbit anti-human
GAPDH was from Cell Signaling Technology. Mouse anti-human
CD66b antibodies were obtained from Immunotech (Marseille
Cedex 9, France). The secondary antibodies (DyLight 488-donkey
anti-rabbit, HRP-goat anti-rabbit, HRP-donkey anti-goat,AP-goat
anti-rabbit) were from Dianova (Hamburg, Germany) while Alexa
546-goat anti-mouse IgG was from Molecular Probes (Leiden, The
Netherlands). Protease inhibitor cocktail sets I and III were from
Merck (Darmstadt, Germany). The phosphatase inhibitor cocktail
PhosStop was from Roche Diagnostics (Mannheim, Germany).
IMMUNOHISTOCHEMISTRY AND IMMUNOFLUORESCENCE
Frozen sections of tumor or healthy epithelial tissue were fixed
with BD Cytofix/Cytoperm and incubated with primary anti-
bodies overnight at 4˚C. Secondary (and tertiary reactions, for
colorimetric immunohistochemistry) were performed for 30 min
each at room temperature. Nuclei were counterstained using
Hematoxylin – for immunohistochemistry (Thermo Scientific,
Karlsruhe, Germany) or DRAQ5 – for immunofluorescence (eBio-
science, San Diego, CA, USA). Samples were finally mounted in
Kaisers glycerol gelatine (Merck, Darmstadt, Germany) or in Flu-
oprep (bioMerieux, Marcy l’Etoile, France) and analyzed with a
Zeiss Axioskop 2 microscope (Zeiss, Jena, Germany).
For TMAs, immunohistochemical staining was performed with
an automated staining device (Dako Autostainer; DakoCytoma-
tion, Hamburg, Germany) using rabbit anti-human CORTACTIN
antibodies. Secondary and tertiary immunoreactions were per-
formed with commercially available anti-rabbit IgG detection kit
(En-Vision; DakoCytomation, Hamburg, Germany). Analysis was
performed with a Zeiss Axioscope 2 microscope. Staining and
analysis of TMAs with CD66b antibodies has been described
previously (Trellakis et al., 2011).
FLOW CYTOMETRY
To assess the levels of CORTACTIN after siRNA transfection, FaDu
cells were fixed with BD Cytofix/Cytoperm and incubated with
rabbit anti-CORTACTIN or isotype control antibodies for 1 h
at room temperature. Secondary reactions were performed for
20 min at room temperature using DyLight488-conjugated anti-
rabbit antibodies. Samples were analyzed by flow cytometry with
a BD FACSCanto II flow cytometer (BD, Heidelberg, Germany).
SDS-PAGE ANDWESTERN BLOT ANALYSIS
FaDu cells (106 cells/sample) were lysed with a buffer contain-
ing 25 mM HEPES (pH 7.3), 0.1% sodium dodecylsulfate (SDS),
1% Triton X-100, 10 mM EDTA, 10 mM sodiumpyrophosphate,
10 mM NaF, 125 mM NaCl, 1% protease inhibitor cocktail I, 1%
protease inhibitor cocktail III, and 10% PhosStop. Cell debris
was removed by centrifugation and the lysates were incubated
with SDS-sample buffer (final concentrations 50 mM Tris pH
6.8, 4% glycerin, 0.8% SDS, 1.6% β-mercaptoethanol, and 0.04%
bromophenol blue). Samples were further processed by SDS-
PAGE and immunoblotting, respectively, as previously described
(Dumitru et al., 2012a).
STATISTICAL ANALYSIS
For the in vitro studies, data are presented as means and SD and sta-
tistical analysis was performed with the two-tailed paired Student’s
t -test. Clinical data was analyzed with the SPSS statistical software
version 18.0 (SPSS Inc, Chicago, IL, USA). Survival curves (5-years
cutoff) were plotted according to the Kaplan–Meier method and
significance was tested using univariate analysis (log-rank test) or
multivariate Cox regression analysis. Correlation between COR-
TACTIN phosphorylation and neutrophilic infiltration was tested
with Spearmans’s rank correlation coefficient (Spearmanρ). Com-
parison of: (i) CORTACTIN expression with clinicopathological
variables [T-stage and lymph node metastasis (N-stage)] or (ii)
CORTACTIN phosphorylation with high versus low neutrophilic
infiltration, respectively, was performed with the χ2 test. In all
studies, the level of significance was set at p≤ 0.05.
RESULTS
CORTACTIN IN OROHYPOPHARYNX CARCINOMA: EXPRESSION AND
SCORING SYSTEM
Using AMIDA technology (Rauch et al., 2004) we initially screened
for potential tumor-associated antigens in HNC patients (see
Materials and Methods). Subsequently, we performed an exten-
sive literature search to select the antigens which might enhance
the aggressiveness and progression of tumors. Thus, we identified
CORTACTIN as a promising candidate. We then determined the
expression of CORTACTIN by immunohistochemical analysis of
TMAs from 89 orohypopharynx carcinoma patients. Additionally,
we determined CORTACTIN expression in frozen orohypophar-
ynx carcinoma tissues (n= 16) versus healthy epithelial tissues
from buccal mucosa (n= 12). CORTACTIN expression was scored
as intensity of staining multiplied by the percentage of positive
cells [immunoreactive score (IRS); Figure 1A]. An IRS of 1–4 was
considered as weak CORTACTIN, IRS 6–8 as medium, and IRS
9–12 represented strong CORTACTIN levels (Figure 1A). Interest-
ingly, in healthy epithelial tissues we observed weak and medium
levels of CORTACTIN, but no strong CORTACTIN expression
(Figure 1B). Consequently, we considered that weak and medium
CORTACTIN represent basal levels of the protein (from here
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FIGURE 1 | CORTACTIN expression and scoring in tissue microarrays.
Malignant orohypopharyngeal and healthy epithelial tissues were stained
against CORTACTIN. (A) The immunoreactive score (IRS) was calculated
as intensity of the staining reaction multiplied by the percentage of
positive cells. Based on the IRS values, CORTACTIN was scored as weak,
medium, and strong. (B) Representative micrographs indicating that
strong levels of CORTACTIN are found only in malignant tissues, while
healthy epithelial tissues displayed either weak or medium levels of
CORTACTIN. Subsequently, the weak and medium CORTACTIN-
expressing specimens were considered as “CORTACTINlow” while strong
CORTACTIN-expressing specimens were termed “CORTACTINhigh.”
Magnification=200×.
on termed “CORTACTINlow”), while strong CORTACTIN rep-
resents overexpressed levels of the protein (from here on termed
“CORTACTINhigh”).
CORTACTIN AND CLINICAL OUTCOME IN OROHYPOPHARYNX
CARCINOMA PATIENTS
Next, we determined whether CORTACTIN levels associated
with 5-years survival, T-stage, and lymph node metastasis (N-
stage) in orohypopharynx carcinoma patients. Here and through-
out the whole study, T-stage was expressed as T1, T2, T3,
T4, while N-stage was expressed as either N0, N1, N2a, N2b,
N2c/N3 (advanced regional lymphadenopathy), or as unilat-
eral (N1, N2a, N2b) versus bilateral (N2c) lymph node metas-
tasis. The results demonstrated that patients with high levels
of tumoral CORTACTIN had significantly shorter overall sur-
vival (p= 0.028, log-rank) than patients with CORTACTINlow
(Figure 2A). Furthermore,χ2 analysis indicated that patients with
advanced disease were more likely to express high levels of COR-
TACTIN than patients with earlier stages of disease (p= 0.027
for T2 versus T4; p= 0.008 for T1–2 versus T3–4; p= 0.005 for
N2a versus N2c-3; p= 0.016 for N unilateral versus bilateral).
The distribution of patients with high and low expression of
CORTACTIN in relation to T-stage and N-stage is depicted in
Figures 2B–D.
CORTACTIN AND NEUTROPHILIC INFILTRATION IN OROHYPOPHARYNX
CARCINOMA
Accumulating evidence indicates a critical role of tumor-
infiltrating immune cells in the progression of different types
of solid cancers. Recently, we demonstrated that high num-
bers of tumor-infiltrating neutrophils (CD66bhigh) associated
with higher T-stage and poor survival in orohypopharynx car-
cinoma patients with advanced disease (Trellakis et al., 2011).
Evaluation of the entire cohort of or hypopharynx carcinoma
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FIGURE 2 | CORTACTIN overexpression associates with
advanced disease and poor clinical outcome in orohypopharynx
carcinoma patients. (A) Kaplan–Meier 5-years survival curves were
plotted for patients with low versus high tumoral CORTACTIN
expression and statistical analysis was performed with the log-rank
test. Graphical depiction of (B) T-stage, (C) N-stage, and (D) laterality
of lymph node metastasis in patients with low CORTACTIN versus
high CORTACTIN expression. Statistical analysis was performed with
the χ2 test (p=0.027 for T2 versus T4; p= 0.008 for T1–2 versus
T3–4; p=0.005 for N2a versus N2c-3; p=0.016 for N unilateral
versus bilateral). The absolute patient numbers are indicated above
each bar of the graphs.
patients showed that high neutrophilic infiltration tended to asso-
ciate with poor survival in those patients (p= 0.054; Figure 3A).
Additionally, we found that patients with advanced N-stage
were more likely to exhibit high neutrophilic infiltration than
patients with earlier N-stages (p= 0.005 for N1 versus N2c/N3;
p= 0.015 for N2b versus N2c/N3; p= 0.001 for N unilateral ver-
sus bilateral; χ2). The distribution of patients with high and
low neutrophilic infiltration in relation to N-stage is depicted in
Figure 3B.
Next, we investigated the combined effect of CORTACTIN
and neutrophilic infiltration on the clinical outcome of oro-
hypopharynx carcinoma patients. To this end, we divided
the patients into four groups (CORTACTINlow/CD66blow,
CORTACTINlow/CD66bhigh, CORTACTINhigh/CD66blow, and
CORTACTINhigh/CD66bhigh) and determined the survival, T-
stage, and the rate of lymph node metastasis. The results demon-
strated that CORTACTINhigh/CD66bhigh patients had the shortest
overall survival (p= 0.010, log-rank; Figure 4A). In further analy-
sis we performedχ2 tests for CORTACTINhigh/CD66bhigh patients
versus the other three groups of patients taken together. The results
indicated that patients with advanced T-stage were more likely to
express synchronous high levels of CORTACTIN and neutrophilic
infiltration than patients with earlier stages of disease (p= 0.036
for T1 versus T4; p= 0.041 for T2 versus T3; p< 0.001 for T2
versus T4; p< 0.001 for T1–2 versus T3–4). Similar results were
obtained for patients with advanced N-stage (p= 0.042 for N0
versus N2c/N3; p= 0.007 for N1 versus N2c/N3; p= 0.023 for
N2a versus N2c/N3; p= 0.003 for N2b versus N2c/N3; p< 0.001
for N unilateral versus bilateral). The distribution of patients with
various combinations of CORTACTIN/CD66b levels in relation to
T-stage and N-stage is depicted in Figures 4B–D. To confirm the
prognostic value of CORTACTIN and neutrophilic infiltration for
the survival of orohypopharynx carcinoma patients, we performed
multivariate Cox regression analysis in a model adjusted for the
type of therapy received, smoking/alcohol consumption and gen-
der. The results showed that the CORTACTINhigh/CD66bhigh phe-
notype was the only significant predictor for poor survival in these
patients (HR= 2.34, 95% CI= 1.01–5.38, p= 0.045; Table 2).
Taken together these data indicate that only the simultaneous
presence of high tumoral CORTACTIN levels and high numbers
of neutrophils associates with poor clinical outcome in orohy-
popharynx carcinoma patients. Furthermore, our findings suggest
that CORTACTIN and neutrophils might functionally“cooperate”
to enhance the progression of orohypopharynx carcinoma in vivo.
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FIGURE 3 | High neutrophilic infiltration associates with poor survival
and metastasis to the lymph nodes in orohypopharynx carcinoma
patients. (A) Kaplan–Meier 5-years survival curves were plotted for patients
with low versus high neutrophilic infiltration and statistical analysis was
performed with the log-rank test. (B) Graphical depiction of N-stage in
patients with high versus low neutrophilic infiltration. Statistical testing was
performed with the χ2 test (p=0.005 for N1 versus N2c/N3; p=0.015 for
N2b versus N2c/N3; p=0.001 for N unilateral versus bilateral). Patients with
high numbers of infiltrating neutrophils (CD66bhigh) are depicted in black,
while patients with low numbers of infiltrating neutrophils (CD66blow) are
depicted in gray. The absolute patient numbers are indicated above each bar
of the graphs.
FIGURE 4 | High CORTACTIN and high neutrophilic infiltration
(CD66b) associate with the most unfavorable clinical outcome.
Analysis of (A) 5-years survival, (B) T-stage, (C) N-stage, and (D) laterality
of lymph node metastasis in patients with various combinations of
CORTACTIN levels and neutrophilic infiltration, respectively. Statistical
testing was performed with the log-rank test (for survival) and with the χ2
test for the remaining clinical parameters (p=0.036 for T1 versus T4;
p=0.041 for T2 versus T3; p<0.001 for T2 versus T4; p<0.001 for T1–2
versus T3–4; p=0.042 for N0 versus N2c/N3; p=0.007 for N1 versus
N2c/N3; p=0.023 for N2a versus N2c/N3; p=0.003 for N2b versus
N2c/N3; p<0.001 for N unilateral versus bilateral). The absolute patient
numbers are indicated above each bar of the graphs.
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Table 2 | Multivariate Cox regression analysis of CORTACTIN and
neutrophilic infiltration adjusted for type of therapy, smoking/alcohol
consumption, and gender.
Cox regression multivariate Hazard ratio for survival
HR 95% CI p-Value
CORTACTIN/CD66b
CORTACTINlow/CD66blow 1
CORTACTINlow/CD66bhigh 1.26 0.50–3.19 0.617
CORTACTINhigh/CD66blow 1.37 0.54–3.50 0.502
CORTACTINhigh/CD66bhigh 2.34 1.01–5.38 0.045*
THERAPY
Surgery 1
Radio(chemo)therapy 1.61 0.41–6.36 0.493
Surgery+ radio(chemo)therapy 1.34 0.36–4.98 0.662
ALCOHOL/TOBACCO
None 1
Tobacco 0.97 0.28–3.37 0.970
Alcohol 0.61 0.06–6.12 0.611
Both 1.39 0.57–3.79 0.518
GENDER
Female 1
Male 2.04 0.88–4.73 0.093
HR, hazard ratio; 95% CI, 95% confidence interval. The asterisk (*) indicates the
parameters showing statistical significance (p≤0.05).
TUMORAL CORTACTIN AND NEUTROPHILS: MECHANISMS OF
INTERACTION
In a further set of studies we sought to clarify the relation-
ship between tumoral CORTACTIN and neutrophils by using
an in vitro system well established in our group and previously
described (Dumitru et al., 2011). This system mimics the recip-
rocal (bi-directional) interaction of tumor cells and neutrophils
in the tumor microenvironment. As illustrated in Figure 5A,
neutrophils are “primed” by tumoral factors and, subsequently,
exert feed-back effects on the tumor cells (Figure 5A). We ini-
tially tested whether neutrophils might upregulate the expres-
sion of CORTACTIN in the tumor cells. To this end, FaDu cells
(hypopharynx carcinoma) were stimulated with factors released
by the “primed” neutrophils (FaDu/neutrophil SN). As control
we used supernatants containing only tumoral factors (FaDu
SN) or supernatants from “un-primed” neutrophils (neutrophil
SN). We initially assessed the total levels of CORTACTIN in a
time-course by western blot. We did not observe a significant
change in CORTACTIN expression upon stimulation by neu-
trophils (Figure 5B – upper panel). However, when the samples
were tested for phosphorylated CORTACTIN, we found increased
levels of phospho-CORTACTIN in tumor cells exposed to factors
released by the “primed” neutrophils (Figure 5B – middle panel).
Next, we tested whether neutrophil-induced phosphorylation
of CORTACTIN might occur also in vivo. To this end, we stained
consecutive sections from frozen orohypopharynx carcinoma tis-
sues (37 patients) against total and phosphorylated (Tyr421)
forms of CORTACTIN, respectively. All samples were co-stained
against CD66b (neutrophil marker). Micrographs were taken at
100-fold magnification from the same region of the tumor tissue
for CORTACTIN or phospho-CORTACTIN (each with CD66b
co-staining). The micrographs were analyzed with the ImageJ
software and the values obtained were considered as Arbitrary Flu-
orescent Units (AFU). We then plotted the levels of CORTACTIN
phosphorylation [phospho-CORTACTIN (AFU)] against the lev-
els of neutrophilic infiltration [CD66b (AFU); Figure 6A]. Statisti-
cal analysis using Spearman’s rank test indicated that CORTACTIN
phosphorylation significantly correlated with neutrophilic infil-
tration (p< 0.001, ρ = 0.620). Additionally, we divided the
patients into CD66blow and CD66bhigh according to the median
value of CD66b (AFU) and found that CD66bhigh patients had sig-
nificantly higher CORTACTIN phosphorylation than CD66blow
patients (p= 0.029, χ2; Figure 6B). A representative example of
CORTACTIN phosphorylation in CD66blow versus CD66bhigh
patients is shown in Figure 6C. Taken together, our in vitro
and in situ studies demonstrate that neutrophils interact with
the tumor cells by inducing CORTACTIN phosphorylation and
activation.
TUMORAL CORTACTIN – NEUTROPHIL INTERACTION: FUNCTIONAL
CONSEQUENCES
Finally, we investigated which functional changes might neu-
trophils induce in the tumor cells via CORTACTIN. Based on the
findings that: (i) CORTACTIN is an important regulator of cellular
migration (Ammer and Weed, 2008) and (ii) neutrophils enhance
the migration of HNC cells (Dumitru et al., 2011), we hypoth-
esized that neutrophils “exploit” high tumoral CORTACTIN lev-
els to promote the migration of the tumor cells. Conversely, in
the absence of tumoral CORTACTIN, neutrophils would not be
able to stimulate the migration of the tumor cells. We, therefore,
knocked-down CORTACTIN in FaDu cells by siRNA. As control,
FaDu cells were transfected with mock siRNA (Figures 7A,B).
We then determined the migratory potential of the tumor cells
in the presence or absence of factors released by “primed” neu-
trophils. The results showed that mock-transfected FaDu cells
displayed accelerated migration in response to neutrophil stimula-
tion, as indicated by enhanced closure of the detection zone (“gap”;
Figure 7C). In contrast, this effect of neutrophil stimulation was
abolished in CORTACTIN knock-down FaDu cells (Figure 7C).
These findings indicate that, consistent with the results presented
in Figure 4, high levels of tumoral CORTACTIN are required for
neutrophil-induced tumoral migration and progression.
DISCUSSION
Increased effort has been made to identify cellular/molecular
factors that could provide accurate information regarding can-
cer diagnosis, prognosis, and response to therapy. In this study,
we identify tumoral CORTACTIN as a prognostic factor for the
clinical outcome in orohypopharynx carcinoma patients. More
importantly, we demonstrate that combined analysis of tumoral
CORTACTIN and of neutrophilic infiltration in the tumor tis-
sue has higher prognostic impact for the clinical outcome in
these patients. In addition to the clinical findings, our study pro-
vides a biological and mechanistical link between neutrophils and
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FIGURE 5 | Neutrophils phosphorylate CORTACTIN in FaDu
(hypopharynx carcinoma) cells. (A) Neutrophils were “primed” by
co-incubation with FaDu supernatants (FaDu SN) for 24 h. The resulting
supernatants (FaDu/neutrophil SN) were used to stimulate FaDu cells for 24,
48, or 72 h. FaDu SN or neutrophil SN only were used as controls. (B)
CORTACTIN expression and activation were assessed by western blot using
antibodies against total CORTACTIN (upper panel) or phosphorylated
CORTACTIN (Tyr 421; middle panel). GAPDH (lower panel) was used as
control for the quantity and quality of protein lysates. The results are
representative for five independent experiments each.
tumoral CORTACTIN by showing that neutrophils phosphorylate
CORTACTIN in the tumor cells to promote their migration.
The potential role of CORTACTIN as prognostic biomarker has
been previously investigated in different types of cancer (Li et al.,
2008; Wang et al., 2009; Cai et al., 2010; Xu et al., 2010). Several
studies observed that CORTACTIN associated with poor clini-
cal outcome also in HNC patients (Gibcus et al., 2008; Hofman
et al., 2008; Rodrigo et al., 2009). Among the HNC subtypes, COR-
TACTIN has been mainly proposed as a potential biomarker for
laryngeal carcinoma (Gibcus et al., 2008; Rodrigo et al., 2009). Sur-
prisingly, the study of Rodrigo et al. (2009) suggested that, while
having prognostic value in laryngeal carcinoma, CORTACTIN
does not associate with the clinical outcome in pharyngeal car-
cinoma, which is in contrast to our findings. This discrepancy
might result from the different read-outs used to assess COR-
TACTIN (over)expression. While we analyzed directly the protein
levels of CORTACTIN in relation to clinical parameters, the above-
mentioned studies based their statistical analysis mainly on the
gene amplification of CORTACTIN. However, it has been often
shown that protein and gene expression do not perfectly correlate.
In fact, even the study of Rodrigo et al. (2009) found that gene
amplification of CORTACTIN did not correlate to the protein
levels observed by immunohistochemistry in 35% of specimens.
Yet proteins are the ultimate effectors in biological processes and
analysis of protein levels is likely to provide more reliable biologi-
cal insights than analysis of gene expression. Thus, by quantifying
the protein expression of CORTACTIN, our study sheds a new
light on the role of this molecule in the prognosis of HNC.
Of novelty and significance are our findings regarding the inter-
action between tumoral CORTACTIN and neutrophils (CD66b-
positive cells) in orohypopharynx carcinoma. As outlined above,
an association of either CORTACTIN or tumor-infiltrating neu-
trophils with poor clinical outcome in cancer patients has already
been proposed by previous studies (Donskov and von der Maase,
2006; Jensen et al., 2009, 2012; Kuang et al., 2011; Trellakis et al.,
2011; Ilie et al., 2012). However, a link between CORTACTIN
and neutrophils has not been shown in any type of cancer thus
far. Here, we demonstrate that patients exhibiting high levels of
tumoral CORTACTIN together with high neutrophilic infiltra-
tion (CORTACTINhigh/CD66bhigh) have worse clinical outcome
than all other groups of patients in our cohort. These findings
are further substantiated by multivariate analysis adjusted for
factors potentially relevant for progression of orohypopharynx
carcinoma, such as smoking/alcohol consumption, type of ther-
apy, and gender. Within this model, CORTACTINhigh/CD66bhigh
phenotype was the only significant predictor of poor survival for
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FIGURE 6 | Phosphorylated CORTACTIN associates with neutrophilic
infiltration in orohypopharynx carcinoma tissues. Consecutive tumor
tissue sections from 37 orohypopharynx carcinoma patients were stained
against CORTACTIN/CD66b or phospho-CORTACTIN/CD66b. Total
CORTACTIN, phospho-CORTACTIN, and neutrophilic infiltration were
analyzed with the ImageJ software. (A) Correlation between neutrophilic
infiltration and the levels of CORTACTIN phosphorylation. Dotted lines
indicate the 95% CI (confidence interval) for the regression line. Statistical
analysis was performed with Spearman’s rank correlation coefficient
(p<0.001; ρ=0.620). (B) The level of CORTACTIN phosphorylation in
patients with low (n=19) versus high (n=18) neutrophilic infiltration.
Shown are the medians (black lines) and percentiles (25th and 75th) as
vertical boxes with error bars; outliers are indicated as small circles.
Statistical analysis was performed with the χ2 test (p=0.029). (C)
Representative micrographs (magnification=200×) of CORTACTIN
phosphorylation in patients with low versus high neutrophilic infiltration.
Green, CORTACTIN or phospho-CORTACTIN; red, CD66b (neutrophils); blue
pseudocolor, DRAQ5 (nuclear staining).
orohypopharynx carcinoma patients. Although necessary to be
confirmed by a larger study incorporating all REMARK guidelines,
CORTACTIN, and tumor-infiltrating neutrophils seem, never-
theless, to be promising biomarker candidates for an accurate
prognosis in orohypopharynx carcinoma.
Our clinical findings also suggest that neutrophils (indirectly)
interact with the tumor cells via CORTACTIN to enhance the
progression of orohypopharynx carcinoma. This interaction is
confirmed by our in vitro and in situ studies which show that
neutrophils activate (phosphorylate) tumoral CORTACTIN to
promote the migration of the tumor cells. These findings are highly
relevant, since the molecular mechanisms of tumor-neutrophil
interactions are still not completely understood. Previous studies
showed that neutrophils have pro-angiogenic effects, or promote
migration, invasion, and proliferation of the tumor cells (Gre-
gory and Houghton, 2011; Dumitru et al., 2012b). With regard
to regulation of tumoral motility/migration by neutrophils, sev-
eral potential mechanisms have been recently proposed. In breast
carcinoma, neutrophils were shown to cluster tumoral ICAM-
1 and phosphorylate FAK (focal adhesion kinase) and paxillin
via src, as well as p38-MAPK via Rho-GTPase (Strell et al.,
2010). In hepatocellular carcinoma, neutrophils were activated
by tumor-derived hyaluronan binding to TLR4 on their surface
and promoted tumor cell motility (Wu et al., 2011). Notably, both
of the above-mentioned studies indicated that the pro-migratory
effects of neutrophils are mediated via direct cell-to-cell contact.
In our system, neutrophils activated CORTACTIN and enhanced
tumor migration via release of soluble factors. Thus, besides sup-
porting the association of CORTACTIN and neutrophils with
increased metastasis in cancer patients, these findings unravel
a novel mechanism of neutrophil-mediated tumor migration
and progression. We certainly do not exclude that, other infil-
trating immune cells (in particular macrophages) enhance the
aggressiveness of orohypopharynx carcinoma in vivo. However,
extensive work is still required to dissect the relative impor-
tance of various immune cell subsets in progression of solid
cancers.
In summary, our study combines clinical and experimental
approaches to provide evidence for a clinically relevant mechanism
of tumor immunomodulation by stromal neutrophils. Ultimately,
these findings contribute to a better understanding of the tumor
microenvironment and foster the development of improved thera-
peutic strategies against orohypopharynx carcinoma and, perhaps,
other types of solid cancer as well.
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FIGURE 7 | Neutrophils promote the migration of FaDu cells via
CORTACTIN. (A) FaDu cells in which CORTACTIN had been knocked-down by
siRNA were stimulated with FaDu/neutrophil SN and migration was assessed
48 h later. (B) Efficiency of CORTACTIN knock-down was determined by flow
cytometric analysis of total CORTACTIN levels at 72 h post-transfection. (C)
FaDu cells (transfected with CORTACTIN or mock siRNA) were grown to
confluency in the presence of “gap”-forming culture inserts. The “gap” refers
to the cell-free round area visible in the figure. Stimulation was performed as
indicated in A. Cells were fixed/stained with a solution containing crystal
violet and micrographs were taken at 25-fold magnification. “Gap”-closure
was quantified with the ImageJ software. Data are means±SD of three
independent experiments (upper panel). A representative result is shown in
the lower panel of the figure. Statistical testing was performed with the
two-tailed paired Student’s t -test.
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